Live feed07:00:00·36dPRReleaseOKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal PainOKYO· OKYO Pharma LimitedHealth CareOriginal source
